0001209191-19-023681.txt : 20190404 0001209191-19-023681.hdr.sgml : 20190404 20190404171111 ACCESSION NUMBER: 0001209191-19-023681 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190402 FILED AS OF DATE: 20190404 DATE AS OF CHANGE: 20190404 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PENHOET EDWARD CENTRAL INDEX KEY: 0001198332 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36561 FILM NUMBER: 19732875 MAIL ADDRESS: STREET 1: ONE EMBARCADERO CENTER SUITE 3700 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNE DESIGN CORP. CENTRAL INDEX KEY: 0001437786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262007174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1616 EASTLAKE AVENUE E. STREET 2: SUITE 310 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: (650) 392-8350 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD STREET 2: SUITE 250 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Immune Design Corp. DATE OF NAME CHANGE: 20090702 FORMER COMPANY: FORMER CONFORMED NAME: VACCSYS INC DATE OF NAME CHANGE: 20080617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-04-02 0 0001437786 IMMUNE DESIGN CORP. IMDZ 0001198332 PENHOET EDWARD C/O IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E., SUITE 310 SEATTLE WA 98102 1 0 0 0 Stock Option (Rt to Buy) 1.48 2019-04-02 4 D 0 3058 D Common Stock 3058 0 D Stock Option (Rt to Buy) 1.23 2019-04-02 4 D 0 4281 D Common Stock 4281 0 D Stock Option (Rt to Buy) 5.60 2019-04-02 4 D 0 10000 D Common Stock 10000 0 D Stock Option (Rt to Buy) 4.05 2019-04-02 4 D 0 12500 D Common Stock 12500 0 D Stock Option (Rt to Buy) 1.31 2019-04-02 4 D 0 12500 D Common Stock 12500 0 D Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. Not Applicable. /s/ Stephen R. Brady, Attorney-In-Fact 2019-04-04